De Jong, trial summary    PDF trial summary

A randomised clinical trial investigating the effect of enzastaurin + fulvestrant versus Fulvestrant in


AnnOncol2012; 23: ix124.  

Studied treatment
Control treatment

Group sizes-9 / -9

Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design

EndpointX1N1X0N0TE95% CI0,22,01,0

De Jong RS, Sonke GS, Maass N et al. Fulvestrant (FUL)plus enzastaurin (ENZA) vs FUL plus placebo (PBO) inaromatase inhibitor (AI)-resistant metastatic breast cancer(MBC): a randomized, double-blind, phase 2 trial. AnnOncol2012; 23: ix124.     [PMID: ]   link to pdf   add to Mendeley  

Registering number (see trial on
Code Name